ALSO NOTED: Takeda prevails in Actos patent suit; Analyst gets peek at Biovail founder's laptop;

> The U.S. Supreme court refused to reconsider an appeals court ruling that upheld Takeda's patent on its diabetes treatment Actos, a decision that keeps Alphapharm from launching a generic version until 2011. Report [1]

> A former Bank of America analyst who's suing Biovail for defamation is getting access to founder Eugene Melnyk's computer to search for deleted emails. Report [2]

> Taro Pharmaceutical got the tentative nod from the FDA for its copycat form of GlaxoSmithKline's Lamictal (generically lamotrigine), an anti-seizure med also used as a mood stabilizer. Release [3]

> Sinclair Pharma disclosed that non-executive director JeanCharles Tschudin bought 55,000 shares on top of the 20,000 he purchased last week. Report [4]

> Amgen got a badly needed boost with its announcement that its most promising experimental therapy, denosumab, significantly increased bone mineral density in a Phase III trial. Report [5]

> A new report out says that the clinical trial process routinely ignores women, the elderly, minorities, the disabled and people living in rural America. Report [6]

> The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. Report [7]

> Do VC groups love the Web more than biotech? Report [8]

Most popular this week: FDA issues early-warning trifecta. Report [9]

And Finally... Birds do it--select fruits with the highest concentrations of antioxidants, that is. Report [10]